← Back to Analyst Consensus 
HELP Buy
Helus Pharma Inc.
Current Price —
Implied Upside —
Analysts 7
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 22, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Sep 18, 2026 | Barclays | initiate | — → Overweight | — | 53% |
| Aug 20, 2026 | TD Cowen | maintain | Buy → Buy | — | 54% |
| Jul 27, 2026 | Wells Fargo | initiate | — → Overweight | — | 54% |
| Jul 9, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jul 1, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Apr 13, 2026 | TD Cowen | initiate | — → Buy | — | 54% |
| Mar 2, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Dec 3, 2025 | Guggenheim | maintain | Buy → Buy | $48 | 52% |
| Nov 20, 2025 | Canaccord Genuity | maintain | Buy → Buy | $45 | 48% |
| Nov 14, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $55 | 44% |
Price Target Trend
Jul 15, 2026 Oct 26, 2026
EPS Estimates
0q —
+1q —
0y —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days